对林沃塞尔塔马布用于治疗复发性/耐药性多发性骨髓瘤的评估
Zachary M Avigan1, Mohammad A Rattu1, Joshua Richter1
1Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Expert opinion on biological therapy
|February 9, 2025
概括
林沃塞尔塔马布是一种针对BCMA的新型双特异性抗体,在多发性骨髓瘤治疗中显示出有希望的疗效和有利的安全性. 需要进一步的现实研究来确定其在T细胞重定向治疗中的作用.
科学领域:
- 血液学 血液学 血液学
- 在瘤学瘤学.
- 免疫治疗是一种免疫疗法.
背景情况:
- 针对B细胞成熟抗原 (BCMA) 的双特异性抗体疗法为重度预治疗多发性骨髓瘤 (MM) 患者提供了显著的益处.
- 在以后的疗法中,对T细胞重定向策略的最佳选择和测序仍然是一个需要进一步研究的领域.
- 林沃塞尔塔马布是一种新兴的BCMA向双特异性抗体,在LINKER-MM1试验中进行了评估.
研究的目的:
- 为了评估linvoseltamab.b.的疗效和毒性概况.
- 为了比较林沃塞尔塔马布与目前批准的双特异性抗体疗法用于MM.
- 分析剂量差异,细胞因子释放综合征 (CRS) 动力学和间接疗效.
主要方法:
- 林沃塞尔塔马布的药物评估.
- 来自LINKER-MM1试验的疗效和毒性数据的审查.
- 与现有的双特异性抗体疗法间接比较MM.
主要成果:
- 林沃塞尔塔马布的疗效与其他已批准的双特异性抗体相提并论.
- 观察到有利的发病率和细胞因子释放综合征 (CRS) 的发病时间.
- 剂量策略和CRS动力学是关键的差异化因素.
结论:
- 与其他双特异性抗体相比,linvoseltamab具有类似的疗效配置,具有有利的CRS发生率和发病率.
- 需要进一步的现实世界分析来确定林沃塞尔塔马布在MM治疗中的最终作用.
- 这项研究强调了多发性骨髓瘤T细胞重定向疗法的不断发展的景观.
更多相关视频
05:32Multimodal Bioluminescent and Positronic-emission Tomography/Computational Tomography Imaging of Multiple Myeloma Bone Marrow Xenografts in NOG Mice
Published on: January 7, 2019
6.8K
07:29Intramucosal Inoculation of Squamous Cell Carcinoma Cells in Mice for Tumor Immune Profiling and Treatment Response Assessment
Published on: April 22, 2019
11.4K
相关概念视频
02:56Treatment Resistant Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
02:56Treatment Resistent Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...